Pliant Therapeutics, Inc. ( (PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to its investors.
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for fibrotic diseases, with a leading candidate in idiopathic pulmonary fibrosis (IPF) treatment.
In its latest earnings report, Pliant Therapeutics announced the discontinuation of its BEACON-IPF Phase 2b trial following recommendations from data safety monitoring boards due to adverse events, but noted early efficacy evidence. The company also highlighted ongoing developments in its oncology and neuromuscular programs.
Key financial metrics for the fourth quarter of 2024 include research and development expenses of $38.8 million, a net loss of $49.7 million, and cash reserves of $357.2 million. The company continues to advance its oncology program with PLN-101095 and plans to initiate a Phase 1 study for PLN-101325 targeting muscular dystrophies.
Looking ahead, Pliant Therapeutics plans to analyze the BEACON-IPF trial data to determine future steps for bexotegrast’s development, while continuing to progress its other clinical programs. The company remains financially positioned to support its operations over the next year.